Search

Displaying results 5481 - 5490 of 9333 in total
  1. Drug

    Ditazole

    go.drugbank.com/drugs/DB08994
    ApprovedWithdrawn

    Ditazole's analgesic and antipyretic effects are similar to phenylbutazone. Additionally, ditazole is a platelet aggregation inhibitor marketed in Spain and Portugal with trade name Ageroplas.

  2. Drug

    Magnesium orotate

    go.drugbank.com/drugs/DB13786
    Experimental

    It is a source of magnesium and is used as a mineral supplement to treat Mg deficiency. Orotic acid acts as a transporter that carries magnesium into the cells. … It also exhibits antioxidant properties, since it is a key intermediate in the biosynthetic pathway of pyrimidines that promotes the synthesis of enzymes which act as free radical scavengers.

  3. Drug

    COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection

    go.drugbank.com/drugs/DB16520
    Experimental

    Presentation Therapeutic Biologics (COVID-19--AP) (AP-TP-Bio))[L31333]. … COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection is an intradermal injection currently being investigated in the clinical trial NCT03348670 (Discovery Stage (Proof-of-concept) COVID-19 Antigen

  4. Drug

    AAV1-FS344

    go.drugbank.com/drugs/DB17855
    Investigational

    AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor. … It is being investigated for the treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and inclusion body myositis.[L46742, L46747, L46752]

  5. Drug

    SOBI-003

    go.drugbank.com/drugs/DB15451
    Investigational

    It is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients).

  6. Drug

    XmAb 2513

    go.drugbank.com/drugs/DB06324
    Investigational

    XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. … It has been investigated for the treatment of hodgkin’s lymphoma.

  7. Drug

    PRGN-3006

    go.drugbank.com/drugs/DB17229
    Investigational

    PRGN-3006 are autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane-bound interleukin-15, and a truncated form of human HER1T (kill switch) on the cell surface

    Synonyms: PRGN-3006 UltraCAR-T, Autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane bound Interleukin-15, and a truncated form of human HER1t (kill switch) on the cell surface
  8. Drug

    OSI-930

    go.drugbank.com/drugs/DB05913
    Investigational

    OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. … OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2).

  9. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). … The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).

  10. Drug

    Triazavirin

    go.drugbank.com/drugs/DB15622
    Investigational

    [L12087] Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19.[A191625] … Triazavirin is a guanine nucleotide analog antiviral originally developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain.